HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

J&J axes $5B CAR-T dream months after touting best-in-disease efficacy

Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north of $5 billion.

By FierceBiotech · May 4, 2026 · via FierceBiotech
J&J axes $5B CAR-T dream months after touting best-in-disease efficacy

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
PipelineFiercePharma ↗
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
The early FDA approval doesn't change Pfizer and Arvinas' plan to leave commercialization of the drug to a yet…
May 4, 2026
Axsome Wins FDA Nod for Auvelity in Alzheimer’s Agitation
PipelineBriefing
Axsome Wins FDA Nod for Auvelity in Alzheimer’s Agitation
Auvelity, already cleared for depression, becomes the first non-antipsychotic treatment for agitation in Alzhe…
May 4, 2026
Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
PipelineFiercePharma ↗
Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ s…
May 3, 2026